Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
- Written by PR Newswire
 |
- The first and only lipolytic injectable for large area – CBL-514's last Phase 2b study has been completed
- Both CBL-514 Phase 2b studies used efficacy assessment tools, AFRS and MRI, in accordance with the U.S. FDA recommendation
- CBL-514 Pivotal Phase 3 study is expected to initiate subject recruitment in H2 2025
NEW TAIPEI CITY, Oct. 24, 2024 /P...
Read more: Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
